Immunocore Holdings plc Contract with Customer, Liability, Noncurrent
Immunocore Holdings plc (IMCR) had Contract with Customer, Liability, Noncurrent of $4.49 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Noncurrent › Liabilities, Other than Long-Term Debt, Noncurrent › Deferred Revenue, Noncurrent
us-gaap:ContractWithCustomerLiabilityNoncurrent · last filed 2026-08-06
- 2026-06-30: Contract with Customer, Liability, Noncurrent $4.49M.
- 2026-03-31: Contract with Customer, Liability, Noncurrent $4.62M.
- 2025-12-31: Contract with Customer, Liability, Noncurrent $4.86M.
- 2025-09-30: Contract with Customer, Liability, Noncurrent $5.00M.
| Period end | Contract with Customer, Liability, Noncurrent |
|---|---|
| 2026-06-30 | $4.49M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $4.62M 10-Q · filed 2026-05-06 |
| 2025-12-31 | $4.86M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $5.00M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $5.25M 10-Q · filed 2025-08-07 |
| 2024-12-31 | $5.43M 10-K · filed 2026-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |